Suppr超能文献

乳腺癌肺微小转移至巨转移进展的临床前模型的建立与鉴定。

Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression.

机构信息

DormaTarg, Inc., Oklahoma City, Oklahoma, United States of America.

DormaTarg, Inc., Oklahoma City, Oklahoma, United States of America; Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, United States of America.

出版信息

PLoS One. 2014 May 30;9(5):e98624. doi: 10.1371/journal.pone.0098624. eCollection 2014.

Abstract

Most cancer patients die with metastatic disease, thus, good models that recapitulate the natural process of metastasis including a dormancy period with micrometastatic cells would be beneficial in developing treatment strategies. Herein we report a model of natural metastasis that balances time to complete experiments with a reasonable dormancy period, which can be used to better study metastatic progression. The basis for the model is a 4T1 triple negative syngeneic breast cancer model without resection of the primary tumor. A cell titration from 500 to 15,000 GFP tagged 4T1 cells implanted into fat pad number four of immune proficient eight week female BALB/cJ mice optimized speed of the model while possessing metastatic processes including dormancy and beginning of reactivation. The frequency of primary tumors was less than 50% in animals implanted with 500-1500 cells. Although implantation with over 10,000 cells resulted in 100% primary tumor development, the tumors and macrometastases formed were highly aggressive, lacked dormancy, and offered no opportunity for treatment. Implantation of 7,500 cells resulted in >90% tumor take by 10 days; in 30-60 micrometastases in the lung (with many animals also having 2-30 brain micrometastases) two weeks post-implantation, with the first small macrometastases present at five weeks; many animals displaying macrometastases at five weeks and animals becoming moribund by six weeks post-implantation. Using the optimum of 7,500 cells the efficacy of a chemotherapeutic agent for breast cancer, doxorubicin, given at its maximal tolerated dose (MTD; 1 mg/kg weekly) was tested for an effect on metastasis. Doxorubicin treatment significantly reduced primary tumor growth and lung micrometastases but the number of macrometastases at experiment end was not significantly affected. This model should prove useful for development of drugs to target metastasis and to study the biology of metastasis.

摘要

大多数癌症患者死于转移性疾病,因此,能够重现包括微转移细胞休眠期在内的自然转移过程的良好模型将有助于开发治疗策略。在此,我们报告了一种自然转移模型,该模型平衡了完成实验的时间和合理的休眠期,可以更好地研究转移进展。该模型的基础是一种未经原发性肿瘤切除的 4T1 三阴性同源乳腺癌模型。将 500 至 15000 GFP 标记的 4T1 细胞以细胞滴定的方式植入免疫功能正常的 8 周龄雌性 BALB/cJ 小鼠的第四脂肪垫中,优化了模型的速度,同时具有包括休眠和重新激活开始在内的转移过程。植入 500-1500 个细胞的动物中原发性肿瘤的发生率低于 50%。尽管植入超过 10000 个细胞会导致 100%的原发性肿瘤发展,但形成的肿瘤和大转移瘤具有高度侵袭性,缺乏休眠期,且没有治疗机会。植入 7500 个细胞会导致 10 天内>90%的肿瘤形成;植入后两周,肺部有 30-60 个微转移(许多动物也有 2-30 个脑微转移),五周时出现第一个小的大转移;许多动物在五周时出现大转移,植入后六周动物濒死。使用最佳的 7500 个细胞,测试了一种乳腺癌化疗药物阿霉素(剂量为最大耐受剂量(MTD),即每周 1 毫克/千克)对转移的疗效。阿霉素治疗显著抑制了原发性肿瘤的生长和肺部微转移,但实验结束时大转移的数量没有明显减少。该模型应有助于开发针对转移的药物,并研究转移的生物学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a3b/4039511/8f00f4dd3fa9/pone.0098624.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验